Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Although the main focus of immuno-oncology has been manipulating the adaptive immune system, harnessing both the innate and adaptive arms of the immune system might produce superior tumour reduction and elimination. Tumour-associated macrophages often have net pro-tumour effects, but their embedded location and their untapped potential provide impetus to discover strategies to turn them against tumours. Strategies that deplete (anti-CSF-1 antibodies and CSF-1R inhibition) or stimulate (agonistic anti-CD40 or inhibitory anti-CD47 antibodies) tumour-associated macrophages have had some success. We hypothesized that pharmacologic modulation of macrophage phenotype could produce an anti-tumour effect. We previously reported that a first-in-class selective class IIa histone deacetylase (HDAC) inhibitor, TMP195, influenced human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro. Here, we utilize a macrophage-dependent autochthonous mouse model of breast cancer to demonstrate that in vivo TMP195 treatment alters the tumour microenvironment and reduces tumour burden and pulmonary metastases by modulating macrophage phenotypes. TMP195 induces the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumours. Furthermore, combining TMP195 with chemotherapy regimens or T-cell checkpoint blockade in this model significantly enhances the durability of tumour reduction. These data introduce class IIa HDAC inhibition as a means to harness the anti-tumour potential of macrophages to enhance cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone deacetylase inhibitor, TMP195, polarizes TAMs toward an anti‐tumor phenotype and increases the efficacy of carboplatin, paclitaxel, and anti‐PD‐1 therapies [84].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
The Immunological Genome Project: networks of gene expression in immune cells
The Immunological Genome Project Consortium, Heng, T. S. P., Painter, M. W., Elpek, K., Lukacs-Kornek, V., Mauermann, N., Turley, S. J., Koller, D., Kim, F. S., Wagers, A. J., et al. (2008) · Nature Immunology · doi:10.1038/ni1008-1091 · Cited by 1,864
Self-citation
Research works printed but not linked: 2
- DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL & Coussens LM Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery 1, 54– 67, 10.1158/2159-8274.cd-10-0028 (2011). 22039576 PMC3203524 · DOI · Paper page
- Malhotra D, Fletcher AL, Astarita J, Lukacs-Kornek V, Tayalia P, Gonzalez SF, Elpek KG, Chang SK, Knoblich K, Hemler ME, Brenner MB, Carroll MC, Mooney DJ, Turley SJ & Immunological Genome Project C Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nature immunology 13, 499– 510, 10.1038/ni.2262 (2012). 22466668 PMC3366863 · DOI · Paper page
Cited by
Items 501–568 of 568
Dulal, D., Boring, A. R., Terrero, D., Tiwari, A. K., & Raman, D. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_20
Tan, B., Shi, X., Zhang, J., Qin, J., Zhang, N., Ren, H., Qian, M., Siwko, S. K., Carmon, K. S., Liu, Q., et al. (2023) · doi:10.1158/0008-5472.c.6512403
Data from Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer
Yam, C., Yen, E.-Y., Chang, J. T., Bassett, R. L., Alatrash, G., Garber, H. R., Huo, L., Yang, F., Philips, A. V., Ding, Q., et al. (2023) · doi:10.1158/1078-0432.c.6530597
Self-citationData from Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer
Yam, C., Yen, E.-Y., Chang, J. T., Bassett, R. L., Alatrash, G., Garber, H. R., Huo, L., Yang, F., Philips, A. V., Ding, Q., et al. (2023) · doi:10.1158/1078-0432.c.6530597.v1
Self-citationLiu, D., Yang, J., Dai, Z., Wang, Z., Huang, X., & Xie, C. (2023) · Research Square · doi:10.21203/rs.3.rs-3120720/v1
Gamage, H. E. V., Shahoei, S. H., Albright, S. T., Wang, Y., Smith, A. J., Farmer, R., Fink, E. C., Jacquin, É., Weisser, E., Bautista, R. O., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.14.553229
Dai, Q., Zhu, J., Yang, J., Zhang, C., Yang, W., Pan, B., Yang, X., Guo, W., & Wang, B. (2024) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x305642240327041753
Yuan, W., Wei, F., Ouyang, H., Ren, X., Hang, J., Mo, X., & Liu, Z. (2021) · Figshare · doi:10.6084/m9.figshare.16680138
WITHDRAWN: Epigenetic remodeling of the myeloid landscape of the cancer tumor microenvironment
German, B., Petkovich, D. A., & Ellis, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00002-3
Recent Advances and Clinical Approach to Cancer Treatment with Nanotechnology Derived Biomolecule
Singh, A. P., Akhtar, W., Alam, S., & Naziya, N. (2024) · Pharmaceutical Nanotechnology · doi:10.2174/0122117385297455240508055620 · Cited by 1
Giorgio, E. D., Tolotto, V., Gualandi, N., Colitti, M., Picco, R., Cortolezzis, Y., D’Este, F., Gani, M., Hancock, W. W., Terrosu, G., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4758082/v1
Park, J., Chen, Y.-Y., Cao, J. J., An, J., Yen, R.-W. C., Outen, J. D., Baylin, S. B., & Topper, M. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.04.610116
Ji, H., Dan, H., Shen, W., Jin, T., Yan, H., & Ai, N. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c04353
Epigenetic remodeling of the myeloid landscape of the cancer tumor microenvironment
German, B., Petkovich, D. A., & Ellis, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.90002-x
Wang, S., Zhang, W., Han, Q., Luo, M., Lin, R., Wen, J., & Liu, D. (2024) · Chemical Papers · doi:10.1007/s11696-024-03769-9
“TMP195 administration demonstrates significant inhibition of tumour growth and reduces lung metastasis (Cassetta and Pollard 2017; Guerriero et al. 2017; Moreira et al. 2020; Zhang et al. 2020).”
Alam†, M. S., Padmanabhan, P. K., McArdle, R. P., Lopez‐Ramirez, A., MysoreRajashekara, A., Knopp, J., Kim, G. K., Centeo, M. V., Apkarian, A. V., Swarup, V., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.01.651719
Discovery of Bisindoles that Activate Tumor-Associated Macrophages and Enhance Antitumor Immunity
Zhao, S., Bao, M., & Cai, X. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00232
Yuan, W., Wei, F., Ouyang, H., Ren, X., Hang, J., Mo, X., & Liu, Z. (2021) · Figshare · doi:10.6084/m9.figshare.16680141
Regulation of tumor progression by myeloid cells
Jaya, F. N. M., & Gabrilovich, D. I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00038-2
Yuan, W., Wei, F., Ouyang, H., Ren, X., Hang, J., Mo, X., & Liu, Z. (2021) · Figshare · doi:10.6084/m9.figshare.16680144
Chen, X., Li, C., Zhao, J., Liu, Y., Zhao, Z., Wang, Z., Li, Y., Wang, Y., Guo, L., Li, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25853102
Yuan, W., Wei, F., Ouyang, H., Ren, X., Hang, J., Mo, X., & Liu, Z. (2021) · Figshare · doi:10.6084/m9.figshare.16680135
Lal, J. C., Townsend, M. G., Mehta, A. K., Oliwa, M., Miller, E., Sotayo, A. O., Cheney, E. M., Mittendorf, E. A., Letai, A. G., & Guerriero, J. L. (2021) · Figshare · doi:10.6084/m9.figshare.15122313
Self-citationYuan, W., Wei, F., Ouyang, H., Ren, X., Hang, J., Mo, X., & Liu, Z. (2021) · Figshare · doi:10.6084/m9.figshare.16680132
Liu, Y., Shang, W., Liu, H., Hui, H., Wu, J., Zhang, W., Gao, P., Guo, K., Guo, Y., & Tian, J. (2022) · Figshare · doi:10.6084/m9.figshare.19029573
Chauchet, X., Cons, L., Chatel, L., Daubeuf, B., Didelot, G., Moine, V., Chollet, D., Malinge, P., Pontini, G., Masternak, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19745505
Chauchet, X., Cons, L., Chatel, L., Daubeuf, B., Didelot, G., Moine, V., Chollet, D., Malinge, P., Pontini, G., Masternak, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19745508
Multifaceted roles of HDAC7 in disease and the evolving chemical toolkit for its modulation
Nie, W., Ding, B., Chen, X., Jiang, L., He, Q., Cao, J., & Zhu, C.-L. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130510 · Cited by 1
Smith, A. J., Schrank, Z., Guan, N., Pedroza, D. A., Calderon, S. J., Yuan, X., Zhao, N., Gabriel, Z., Gao, Y., Rivas, C. H., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-26-0278
Strategies of Cancer Immunotherapy : Model of Triple Negative Breast Cancer
Kishi, M. (2019) · theses.fr (ABES) · doi:10.70675/51302a51z120az4319z9cebzc7a90f0976ce · Cited by 1
Activation des lymphocytes T gamma delta dans les cancers
Laplagne, C. (2020) · theses.fr (ABES) · doi:10.70675/7f8ae6ddz0e42z4c41z838fz044b72328b9c
Ferré, A. E. (2021) · theses.fr (ABES) · doi:10.70675/bd3a46adzb3cfz4dfaza13dz05e92e57bbf8 · Cited by 1
Characterization of a novel antibody targeting tumor-associated macrophages
Domagala, M. (2022) · theses.fr (ABES) · doi:10.70675/b4720b22z5236z4e41za89dz1f8d16c27670
NG2-targeting macrophages inhibit 3D invasion of patient-derived glioblastoma spheroidsPreprint
Kurudza, E., Varady, S. R. S., Greiner, D., Marvin, J. E., Ptacek, A., Rodriguez, M., Mishra, A. K., He, G., Dotti, G., Colman, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.03.715398
Reprogramming tumor-associated macrophages using siRNA-loaded lipid nanoparticles
Gul, S. (2025) · theses.fr (ABES) · doi:10.70675/a1043f82z871dz417ezb779z6fa27df750ce
Role of monocytes, macrophages, and polymorphonuclear cells in cancer immunology
Jain, P., Panchal, N., Finley, J., Gupta, S. K., Sandhu, J., & Aggarwal, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41551-7.00008-4
Photo-downregulation of SIRT4 mitigates aging in mice by enhancing H3K9ac via fatty acid metabolismPreprint
Deng, F., Yang, R., Niu, J., Wang, M., Liu, Y., Li, X., Gao, Z., Yang, L., Liu, H., Yang, Y. Q., et al. (2026) · eLife · doi:10.7554/elife.111498
“Class I and II HDACs are both Zn² + - dependent and primarily localized to the nucleus ( Guerriero et al., 2017 ).”
Photo-downregulation of SIRT4 mitigates aging in mice by enhancing H3K9ac via fatty acid metabolismPreprint
Deng, F., Yang, R., Li, X., Niu, J., Gao, Z., Wang, M., Liu, Y., Yang, L., Liu, H., Yang, Y. Q., et al. (2026) · eLife · doi:10.7554/elife.111498.1
Dense stroma limits immunogenic cell death and immunotherapy efficacy in breast cancerPreprint
Tatárová, Z., Moldaner, L., Jakubík, J., Gaidhani, G., Xu, Y., & Blumberg, D. C. (2026) · Research Square · doi:10.21203/rs.3.rs-9896344/v1
HDAC9 promotes atherosclerosis by suppressing CYP7A1 and impairing hepatic cholesterol excretion
Lin, R., Li, M., Liu, J. I. N., He, M., Li, Z., Jin, J., Zhang, R., Zheng, C., Chen, L., Shen, M., et al. (2026) · Clinical Science · doi:10.1042/cs20260062
Li, J., Li, J., Zhao, Y., Yu, Y., & Cui, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1853196
Cytokine-mediated mechanisms of TAM in driving cancer progression
Jamali, M. C., Al-Samawi, R. I., Patel, A. A., Mekkey, S. M., Mallick, A. K., Dawood, S. A., Sadikan, M. Z., Mustafa, A. E. M., Mansuri, N., Qureshi, M. A., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117125 · Cited by 1
Overcoming immunotherapy barriers in pediatric brain tumors: epigenetic strategies
Tetens, A. R., Craig-Schwartz, J., Findlay, T., & Koldobskiy, M. A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1857121
Alimohammadi, M., Mirnejad, A. M., Farahani, N., Hedayati, N., & Hushmandi, K. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06566-x
Metabolic–epigenetic crosstalk in innate immune cell plasticity within the tumor microenvironment
Noh, J., Lee, J., You, C., & Kang, K. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01802-3 · Cited by 1
“Similarly, class IIa HDAC inhibitors such as TMP195 alongside low-dose pan-HDAC blockade reprogram TAMs in breast and colorectal cancers toward an IL-12-producing phenotype to reduce tumor burden and potentiate anti-PD-(L)1 immunotherapy 192 .”
The Role of NLRP3 Inflammasome in Aging and Age-Related Diseases
Başaran, A. (2026) · Uluslararası Sağlık Bilimlerinde Disiplinler Arası Etkileşim Dergisi · doi:10.65349/mnhi7944
Jain, D., & Misra, H. S. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100577
Liu, J., Wang, S., Bao, D., Dong, G., Ma, Y., Zhang, G., Liu, X., Zhang, D., Wang, L., Xu, S., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015703
“Our results suggest that the strategy targeting the RAB31/ CME pathway in TAMs represents a promising and novel option in cancer immunotherapy.”
The plasticity and metabolic reprogramming of macrophage in ulcerative colitis
Zhang, Y., Yang, D., Jiang, J., Wang, D., Ji, F., & Sun, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1903462 · Cited by 2
Photo-downregulation of SIRT4 mitigates aging in mice by enhancing H3K9ac via fatty acid metabolismPreprint
Deng, F., Yang, R., Li, X., Niu, J., Gao, Z., Wang, M., Liu, Y., Yang, L., Liu, H., Yang, Y., et al. (2026) · eLife · doi:10.7554/elife.111498.2
Pan, J., Li, B., Lau, L. Y., Hong, Z., & Chen, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189702 · Cited by 2
McRae, H. M., Nguyen, K. M., Vallmajó-Martín, Q., Rivera, S. A., Stevenson, B. T., Evensen, K. G., Burns, M. J., Bell, J. C., Mandias, H. C. R., Chick, B. Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.25.754528
Yang, J., Cai, X., He, F., 张君红, Zhang, Z., Yi, Z., Xie, C., & Xu, B. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02903-1
LRH-1 is a novel regulator of neutrophil-driven immune responses within the tumor microenvironment
Wang, Y., Duong, B., Keeley, S., Krawczyńska, N., Bendre, S. V., Schane, C. P., Pradeep, D., Rodriguez-Casiano, D., Weisser, E., Vuilleumier, N. C., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218910 · Cited by 1
Heydari, F., Derakhshani, M., & Naghinezhad, J. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01861-z
BindingDB Entry 50013161: HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.
BindingDB (2022) · UC San Diego · doi:10.7270/q2dv1pmp
BindingDB (2024) · UC San Diego · doi:10.7270/q2p55sv5
BindingDB Entry 50008262: Recent advances in class IIa histone deacetylases research.
BindingDB (2021) · UC San Diego · doi:10.7270/q2vm4gmz
Macrophage biology and immunoregulation in health and disease
Zhao, H., Chou, Y.-J., & Huang, S. C. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01486-9
Metadata
- Authors
- Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., Davis, S. P., Lobera, M., Nolan, M. A., & Letai, A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Nolan, Michael A.
- Letai, Anthony
- ORCID
- Venue
- Nature
- Published
- 2017-03
- Volume
- 543
- Issue
- 7645
- Pages
- 428-432
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8170529
- OpenAlex
- W2591627715
- Cited by
- 558
- References
- 35
- Citations by year
- 2026: 35 · 2025: 51 · 2024: 51 · 2023: 63 · 2022: 74 · 2021: 94 · 2020: 68 · 2019: 63 · 2018: 33 · 2017: 25
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA205967, F32CA180733)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- breast cancer, tumour-associated macrophages, antitumor immunity, tumor microenvironment, lung metastasis, chemotherapy synergy, T cell checkpoint blockade, CSF-1
- MeSH terms
- Animals, Benzamides, Breast Neoplasms, Cell Differentiation, Disease Models, Animal, Drug Synergism, Female, Humans, Lung Neoplasms, Macrophage Activation, Macrophages, Oxadiazoles, Phagocytosis, Cell Line, Tumor, Tumor Burden, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.